Pelican Therapeutics Announces Manufacturing Agreement with KBI Biopharma to Advance Cancer-targeting Immunotherapies Sep 27, 2017
Heat Biologics Granted Type C Meeting with FDA to Discuss Registrational Pathway for HS-110 in Combination with Opdivo(R) as a Treatment for Non-Small Cell Lung Cancer Sep 12, 2017
Heat Biologics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York Sep 7, 2017
Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of $15.2 Million CPRIT Grant Award Jun 28, 2017
